A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy

Yingqiang Liu; Linjiang Tong; Mengge Zhang; Qi Zhang; Qiupei Liu; Fang Feng; Yan Li; Mengzhen Lai; Haotian Tang; Yi Chen; Meiyu Geng; Wenhu Duan; Jian Ding; Hua Xie

doi:10.1002/cac2.12521

Cancer Communications ›› 2024, Vol. 44 ›› Issue (3) :438 -442. DOI: 10.1002/cac2.12521

LETTER TO THE JOURNAL

A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy

Yingqiang Liu ¹
, Linjiang Tong ¹
, Mengge Zhang ¹^,²
, Qi Zhang ¹^,²
, Qiupei Liu ¹^,³
, Fang Feng ¹
, Yan Li ¹
, Mengzhen Lai ¹
, Haotian Tang ¹^,⁴
, Yi Chen ¹^,²
, Meiyu Geng ¹^,²^,⁵
, Wenhu Duan ²^,⁵^,⁶^,^†
, Jian Ding ¹^,²^,⁵^,^†
, Hua Xie ¹^,²^,⁴^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Yingqiang Liu, Linjiang Tong, Mengge Zhang, Qi Zhang, Qiupei Liu, Fang Feng, Yan Li, Mengzhen Lai, Haotian Tang, Yi Chen, Meiyu Geng, Wenhu Duan, Jian Ding, Hua Xie. A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy. Cancer Communications, 2024, 44(3): 438-442 DOI:10.1002/cac2.12521

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Martínez-Jiménez F, Muiños F, Sentís I, Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C, et al. A compendium of mutational cancer driver genes. Nature Reviews Cancer. 2020;20(10):555–572.

[2]	Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159.

[3]	Hamarsheh S, Osswald L, Saller BS, Unger S, De Feo D, Vinnakota JM, et al. Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun. 2020;11(1):1659.

[4]	Haston S, Gonzalez-Gualda E, Morsli S, Ge J, Reen V, Calderwood A, et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell. 2023;41(7):1242–1260.e6.

[5]	Liu Y, Zhan Z, Kang Z, Li M, Lv Y, Li S, et al. Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma. Acta Pharmaceutica Sinica B. 2023;13(12):4748–4764.

[6]	Kang Z, Li S, Lin Y, Li Y, Mao Y, Zhang J, et al. A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors. Investigational New Drugs. 2023;41(2):296–305.

[7]	Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang T, et al. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci. 2022;113(2):709–720.

[8]	Zhang T, Qu R, Chan S, Lai M, Tong L, Feng F, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19(1):90.

[9]	Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–5337.